4 August 2025
BerGenBio ASA: Approval of the merger plan and the fully underwritten rights issue
Bergen, 4 August 2025: Reference is made to the joint stock exchange announcement made on 30 June 2025 by BerGenBio ASA (the “Company”) and Oncoinvent ASA (“Oncoinvent”) regarding the contemplated combination of the Company, Oncoinvent and BerGenBio Norge AS though a statutory triangular merger (the “Merger”).
An extraordinary general meeting of the Company was held on 12:00 hours (CEST) today by electronic means through Lumi AGM. All items on the agenda were resolved in accordance with the board of directors’ and the nomination committee’s proposals, including, but not limited to, approval of the merger plan dated 30 June 2025 (the “Merger Plan”) and the fully underwritten rights issue in the Company to raise gross proceeds of NOK 130 million.
As announced by Oncoinvent today, the Merger Plan has been approved by the extraordinary general meeting of Oncoinvent. As a consequence, the decision to approve the Merger will now be filed with the Norwegian Register of Business Enterprises. Completion of the Merger remains subject to customary terms and conditions, as further described in the Merger Plan and the joint stock exchange announcement made on 30 June 2025.
The minutes from the extraordinary general meeting are attached hereto and will also be made available on the Company’s website www.bergenbio.no.
For further information regarding the Merger and the complete terms and conditions for the Merger, please see the Merger Plan with appendices available on www.bergenbio.no.
For further information, please contact:
Olav Hellebø, CEO, BerGenBio ASA, ir@bergenbio.com
Rune Skeie, CFO, BerGenBio ASA, rune.skeie@bergenbio.com
This information is subject to the disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act.
About Oncoinvent
Oncoinvent is developing Radspherin®, a receptor-independent alpha radiation therapy that leverages the unique anatomy of the abdominal cavity to destroy residual micrometastases using a single, highly localized dose of alpha radiation. The initial clinical focus is treatment of ovarian and colorectal cancer patients after surgical removal of the primary tumor and visible metastases in the peritoneum, the thin membrane lining the abdominal cavity and covering the abdominal organs.
This radiopharmaceutical is designed to prevent or delay recurrence in the peritoneal cavity, keeping patients disease-free for longer than the current standard of care and thereby also impacting overall survival. It is broadly applicable to any cancer that spreads to the peritoneum, e.g. ovarian, colorectal, and gastric cancers. Radspherin® stands out for its simplicity, excellent safety profile, and seamless integration into existing surgical workflows. Oncoinvent’s product is easy to use, avoids systemic delivery and significant toxicity. It is also differentiated in being simple to manufacture, scalable, and supply de-risked.
Data from two trials in ovarian (phase 1) and colorectal (phase 1/2a) cancers, are highly promising, showing an excellent safety profile and meaningful signals of efficacy. Interim data from an ongoing, randomized, controlled phase 2 ovarian cancer trial is expected in 2026. With cost-effective manufacturing, blockbuster potential, active pharma partnership momentum, plus strong endorsements from leading experts, Oncoinvent is built for scale and commercial success, and is set to become the new standard for post-surgical cancer care. The Company was founded by the originators of Algeta and Xofigo (acquired by Bayer).
